

Title: RDF1131-22 Head/Neck/Urothelial Cancers

Reference Number: RDF1131-22

Date of Response: 17/01/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

*We are investigating the incidence and treatment of different types of cancer in the UK. We would greatly appreciate if you could answer the below questions:*

- 1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:*

Answer: Please see tables below. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.

In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

	<i>Eastern Services</i>	<i>Northern Services</i>
<i>Carboplatin (monotherapy or in combination with 5-FU)</i>	<5	<5
<i>Cisplatin (monotherapy or in combination with 5-FU)</i>	7	Nil
<i>Cetuximab with/without chemotherapy</i>	Nil	Nil
<i>Cetuximab with radiotherapy</i>	Nil	Nil
<i>Pembrolizumab monotherapy</i>	8	<5
<i>Pembrolizumab with chemotherapy</i>	Nil	Nil
<i>Nivolumab</i>	<5	<5
<i>Docetaxel (monotherapy or in combination with 5-FU)</i>	Nil	Nil
<i>Fluorouracil (5FU)</i>	<5	Nil
<i>Radiotherapy only</i>	16	Nil
<i>Other</i>	Nil	<5

2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:

	<b>Eastern Services</b>	<b>Northern Services</b>
Total number of head and neck cancer patients	36	<5
Number of locally advanced head and neck cancer patients ((patient numbers for Stage 3 head and neck cancer)	Unable to provide figure as staging incomplete for many patients	Unable to provide figure as staging incomplete for many patients
Number of unresectable recurrent and/or metastatic head and neck cancer patients	14	<5

3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:

	<b>Eastern Services</b>	<b>Northern Services</b>
Avelumab	<5	Nil
Atezolizumab	<5	<5
Carboplatin with Gemcitabine	<5	<5
Carboplatin single or in any other combination	Nil	Nil
Cisplatin with Gemcitabine	9	<5
Cisplatin single or in any other combination	Nil	Nil
Nivolumab	Nil	Nil
Pembrolizumab	Nil	Nil
Any other regimen including Paclitaxel	Nil	Nil
Any other chemotherapy regimen	<5	Nil
Other active systemic anti-cancer therapy [please state]	Mitomycin and fluorouracil <5	Nil
Palliative care only	<5	Nil

4. Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Answer: ART-DECO: ≤5; CompARE Trial: ≤5; DARS: ≤5; IoN: 32; PATHOS: 13.

5. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Answer: POUT: 8; RE-ARM: Nil.